Frontline sequential immunochemotherapy plus lenalidomide for mantle cell lymphoma incorporating MRD evaluation: Phase II, investigator-initiated, single-center study Meeting Abstract
| Authors: | Epstein-Peterson, Z. D.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P. A.; Ho, C.; Jacob, A. P.; Laraque, L.; Matasar, M. J.; Moskowitz, A. J.; Moskowitz, C. H.; Mullins, C. D.; Owens, C.; Salles, G.; Schöder, H.; Straus, D. J.; Younes, A.; Zelenetz, A. D.; Kumar, A. |
| Abstract Title: | Frontline sequential immunochemotherapy plus lenalidomide for mantle cell lymphoma incorporating MRD evaluation: Phase II, investigator-initiated, single-center study |
| Meeting Title: | 62nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Dec 5-8 |
| Meeting Location: | Virtual |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-11-05 |
| Language: | English |
| ACCESSION: | WOS:000607205605039 |
| DOI: | 10.1182/blood-2020-136565 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 11 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
